SCHEMBL21543944

SCHEMBL21543944

CC(C)(C)OC(=O)c1c(N)csc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM6 O15303 1/20 0.43
KDM4E B2RXH2 4/20 0.37
CISD2 Q8N5K1 1/20 0.36
ALDH1A1 P00352 5/20 0.35
LMNA P02545 3/20 0.34
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
HPGD P15428 2/20 0.34
PRKCZ Q05513 1/20 0.34
HPGDS O60760 1/20 0.33
MAPT P10636 2/20 0.33
HSD17B10 Q99714 2/20 0.33
GPR35 Q9HC97 1/20 0.33
TDP1 Q9NUW8 2/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
THRB P10828 1/20 0.32
HIF1A Q16665 1/20 0.32
ALOX15 P16050 1/20 0.32
CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8439916 0.87 GRM6 (0.40) GRM6KDM4ECISD2ALDH1A1LMNA
SCHEMBL27719113 0.86 KDM4E (0.49) GRM6KDM4ECISD2ALDH1A1LMNA
SCHEMBL4033414 0.77 ALDH1A1 (0.41) GRM6KDM4ECISD2ALDH1A1LMNA
SCHEMBL27682582 0.77 ALDH1A1 (0.50) KDM4EALDH1A1KMT2AMEN1HPGD
Ethane SCHEMBL27400512 0.76 GRM6 (0.39) GRM6KDM4ECISD2ALDH1A1LMNA
Hydrochloric Acid SCHEMBL4105337 0.75 TDP1 (0.39) KDM4EALDH1A1KMT2AMEN1MAPT
SCHEMBL20303097 0.74 ALDH1A1 (0.42) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL27805811 0.72 GRM6 (0.40) GRM6KDM4ECISD2ALDH1A1LMNA
SCHEMBL27580623 0.72 GRM6 (0.43) GRM6CISD2ALDH1A1LMNAKMT2A
SCHEMBL21543939 0.71 CISD2 (0.44) CISD2ALDH1A1LMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158357-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX, INC. (US) 2024-05-16 US disclosed
EP-4252856-A2 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE Oligomerix, Inc. (US) 2023-10-04 EP disclosed
EP-3558950-B1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX INC (US) 2023-05-10 EP disclosed
CN-114213400-B Thiophene-containing pyrimidine compound and preparation method and application thereof 贵州大学 2022-11-08 CN disclosed
US-11472776-B2 Quinazolinones that inhibit the formation of tau oligomers and their method of use OLIGOMERIX, INC. (US) 2022-10-18 US disclosed
CN-114213400-A Thiophene-containing pyrimidine compound and preparation method and application thereof 贵州大学 2022-03-22 CN disclosed
US-20190345115-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE OLIGOMERIX, INC. 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345115-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE MAPT, PSEN1, APP GRM6 3041/4885KDM4E 3341/4885CISD2 1925/4885
US-11472776-B2 Quinazolinones that inhibit the formation of tau oligomers and their method of use MAPT, PSEN1, APP GRM6 3444/4885KDM4E 2885/4885CISD2 2327/4885
US-20240158357-A1 NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE MAPT, PSEN1, APP GRM6 3041/4885KDM4E 3341/4885CISD2 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.